Last reviewed · How we verify
S6G5T-7
S6G5T-7 is a Small molecule drug developed by Sol-Gel Technologies, Ltd.. It is currently in Phase 2 development.
S6G5T-7 is not mentioned in the provided facts, so it cannot be included in the summary. However, based on the available information, here is a 2-sentence factual summary of S6G5T-1 and S6G5T-3 for Acne Vulgaris: S6G5T-1 and S6G5T-3 are being studied for the treatment of Acne Vulgaris in a Phase 2 clinical trial. The trial is evaluating the efficacy, safety, and tolerability of these treatments in patients with Acne Vulgaris.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | S6G5T-7 |
|---|---|
| Sponsor | Sol-Gel Technologies, Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S6G5T-7 CI brief — competitive landscape report
- S6G5T-7 updates RSS · CI watch RSS
- Sol-Gel Technologies, Ltd. portfolio CI
Frequently asked questions about S6G5T-7
What is S6G5T-7?
Who makes S6G5T-7?
What development phase is S6G5T-7 in?
Related
- Manufacturer: Sol-Gel Technologies, Ltd. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing